Blood biomarkers have made earlier biological detection of Alzheimer's disease possible. But are patients truly benefiting? Scientific discovery alone does not change patient outcomes. Implementation does. The next chapter in Alzheimer's care is no longer about whether p-tau217 works. It is about building the ecosystem that translates innovation into impact. That requires: Physician confidence and education Evidence-based clinical guidelines Regulatory approval and standardiz